SCHEMBL26660436

SCHEMBL26660436

O=C(O)CC(=O)NC1CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.48
KMT2A Q03164 3/20 0.45
HPGD P15428 3/20 0.45
EPHX1 P07099 1/20 0.45
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.43
EPHX2 P34913 3/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C19 P33261 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MMP2 P08253 1/20 0.41
MMP8 P22894 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4978162 0.97 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2KMT2AHPGDEPHX1
SCHEMBL16786337 0.90 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2KMT2AHPGDEPHX1
SCHEMBL307675 0.88 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2KMT2AHPGDEPHX1
SCHEMBL23841258 0.88 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2KMT2AHPGDEPHX1
SCHEMBL13621155 0.81 SIGMAR1 (0.47) ALDH1A1LMNAL3MBTL1
SCHEMBL10015691 0.80 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2KMT2AHPGDEPHX1
SCHEMBL13544566 0.78 SMN1; SMN2 (0.65) ALDH1A1SMN1; SMN2KMT2AHPGDEPHX1
SCHEMBL27892099 0.78 SMN1; SMN2 (0.72) ALDH1A1SMN1; SMN2KMT2AHPGDEPHX1
SCHEMBL10132085 0.78 SMN1; SMN2 (0.65) ALDH1A1SMN1; SMN2KMT2AHPGDEPHX1
SCHEMBL13690844 0.77 KMT2A (0.47) ALDH1A1SMN1; SMN2KMT2AHPGDEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270209-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. 2025-08-28 US disclosed
EP-4522616-A1 LRRK2 INHIBITORS Interline Therapeutics, Inc. (US) 2025-03-19 EP disclosed
CN-119403801-A LRRK2 inhibitors 因特来治疗公司 2025-02-07 CN disclosed
WO-2023220247-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
WO-2023220247-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270209-A1 LRRK2 INHIBITORS LRRK2, PARK7, PINK1 ALDH1A1 2142/4885SMN1; SMN2 766/4885KMT2A 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.